CF Timeline

Events

First comprehensive medical report on CF was written by Dorothy Andersen, M.D.

1938

During a NYC heat wave, Dr. Paul di Sant’Agnese and others connect the extra loss of salt by CF patients to the underlying cellular problem

1953

The Cystic Fibrosis Foundation becomes the National CF Research Foundation and awards the first research grants to Dr. Dorothy Andersen, Dr. Paul di Sant’Agnese, and Dr. Harry Schwachman

1955

The Foundation establishes the accredited care center network, creating 2 care centers devoted to treating CF

1961

30 Foundation-accredited care centers are in operation

1962

The first basic science committee is established to investigate CF at the cellular level and find answers

1964

More than 100 Foundation-accredited care centers are in operation

1978

The Research Development Program, a network of research centers and universities and medical schools nationwide, is established

1982

A group of Foundation-supported scientists find the defective CF gene and its protein product, CFTR

1989

The FDA approves Pulmozyme, a drug that is proven to thin the mucus in the lungs and is the first drug developed specifically for CF

1993

The FDA approves tobramycin, or TOBI, which is the first aerosol antibiotic designed for CF, that was proven to reduce the amount of time a CF patient is in the hospital and improves their lung functi

1997

Foundation-supported scientists map the entire genetic structure of the most common cause of CF lung infections, a bacteria called Pseudomonas aeruginosa

2000

Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), a nonprofit research affiliate of the Foundation, is established to govern drug discovery and development efforts

2000

CFFT-supported studies in Australia and at the University of North Carolina show that inhaled hypertonic saline helps clear CF mucus and improve lung health, so it becomes a therapeutic option

2004

Ivacaftor, an oral drug that targets the faulty CFTR protein, enters clinical trials with the hopes of opening chloride channels that don’t function correctly

2006

Phase 2 studies of Ivacaftor show improvements in the key signs of the disease, and the studies achieve “proof of concept” that it is possible to treat the key signs of CF

2008

FDA approves a new antibiotic, Cayston, an inhaled solution that treats lung infections for people with CF who battle infections and develop a resistance to existing antibiotics

2010

4 more drugs are approved to fight CF

2012 - 2016

The Foundation is still maintaining potential therapies targeting CF in a "pipeline". The more drugs in the pipeline, the greater the odds of producing successful therapies and a cure for CF

2017 - Present